Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift
- PMID: 30770030
- DOI: 10.1177/1479164119827611
Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift
Abstract
While few dispute the existence of the metabolic syndrome as a clustering of factors indicative of poor metabolic health, its utility above that of its individual components in the clinical care of individual patients is questioned. This is likely a consequence of the failure of clinicians and scientists to agree on a unifying mechanism to explain the metabolic syndrome. Insulin resistance has most commonly been proposed for this role and is generally considered to be a root causative factor for not only metabolic syndrome but also for its associated conditions of non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), obesity-related type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). An alternative view, for which evidence is mounting, is that hyper-responsiveness of islet β-cells to a hostile environment, such as westernised lifestyle, is primary and that the resulting hyperinsulinaemia drives the other components of the metabolic syndrome. Importantly, within this new conceptual framework, insulin resistance, while always a biomarker and state of poor metabolic health, is not considered to be harmful, but a protective adaptive response of critical tissues including the myocardium against insulin-induced metabolic stress. This major shift in how metabolic syndrome can be considered puts insulin hypersecretion into position as the unifying mechanism. If shown to be correct, this new conceptual framework has major implications for the future prevention and management of the metabolic syndrome, including its associated conditions of NAFLD, PCOS, obesity-related T2D and ASCVD.
Keywords: Cardiovascular diseases; insulin hypersecretion; insulin resistance; insulin-mediated metabolic stress; metabolic syndrome; non-alcoholic fatty liver disease; polycystic ovary syndrome; type 2 diabetes.
Similar articles
-
Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?Clin Sci (Lond). 2017 Nov 6;131(22):2701-2704. doi: 10.1042/CS20170987. Print 2017 Nov 15. Clin Sci (Lond). 2017. PMID: 29109303
-
Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.Nutr Res Rev. 2017 Jun;30(1):97-105. doi: 10.1017/S0954422416000287. Epub 2017 Feb 22. Nutr Res Rev. 2017. PMID: 28222828 Review.
-
Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.J Gastroenterol Hepatol. 2016 May;31(5):980-7. doi: 10.1111/jgh.13241. J Gastroenterol Hepatol. 2016. PMID: 26589977
-
Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome.J Steroid Biochem Mol Biol. 2018 Jan;175:177-189. doi: 10.1016/j.jsbmb.2016.09.017. Epub 2016 Sep 20. J Steroid Biochem Mol Biol. 2018. PMID: 27662816 Review.
-
Nonalcoholic fatty liver disease in children and adolescents - Relationship with Polycystic Ovary Syndrome.Curr Pharm Des. 2015;21(35):5144-50. doi: 10.2174/1381612821666150928105959. Curr Pharm Des. 2015. PMID: 26412465 Review.
Cited by
-
Gut Microbiota Dysbiosis Ameliorates in LNK-Deficient Mouse Models with Obesity-Induced Insulin Resistance Improvement.J Clin Med. 2023 Feb 22;12(5):1767. doi: 10.3390/jcm12051767. J Clin Med. 2023. PMID: 36902554 Free PMC article.
-
Association of Two Indices of Insulin Resistance Marker with Abnormal Liver Function Tests: A Cross-Sectional Population Study in Taiwanese Adults.Medicina (Kaunas). 2021 Dec 21;58(1):4. doi: 10.3390/medicina58010004. Medicina (Kaunas). 2021. PMID: 35056312 Free PMC article.
-
Glycemic and metabolic sub-classification of prediabetes and risk factors for cardiovascular disease in the D2d cohort.Am J Prev Cardiol. 2023 Jul 27;15:100525. doi: 10.1016/j.ajpc.2023.100525. eCollection 2023 Sep. Am J Prev Cardiol. 2023. PMID: 37650052 Free PMC article.
-
Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis.Trends Endocrinol Metab. 2021 Sep;32(9):721-730. doi: 10.1016/j.tem.2021.06.001. Epub 2021 Jul 12. Trends Endocrinol Metab. 2021. PMID: 34266706 Free PMC article. Review.
-
Upregulation of α-ENaC induces pancreatic β-cell dysfunction, ER stress, and SIRT2 degradation.J Biomed Res. 2024 May 21;38(3):241-255. doi: 10.7555/JBR.37.20230128. J Biomed Res. 2024. PMID: 38769731 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical